Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-Week prospective study

Jun Soo Kwon, Joon Hwan Jang, Do Hyung Kang, So Young Yoo, Yong Ku Kim, Seong Jin Cho, Hyun Yoon Bo, Seok Jeong Bum, Ook Lee Byung, Hyung Kim Chan, Yoon Kim Chang, Chi Un Pae, Eung Kim Chul, Hoon Kim Do, Seok Yang Dong, Duk In Jon, Jae Jin Kim, Gong Cyn Jae, Jeong Ho Seok, Gee Kim JeongJong Il Lee, Jung Seo Yi, Goo Lee Jung, Sue Hong Kyung, Min Soo Lee, Ick Lee Sang, Yeol Lee Sang, Woo Lee Sun, Tak Youn, Won Myong Bahk, Yanghyun Lee, Chul Chung Young, Chul Shin Young, Hoon Kim Young

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression-Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-naïve patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.

Original languageEnglish
Pages (from-to)73-81
Number of pages9
JournalPsychiatry and Clinical Neurosciences
Volume63
Issue number1
DOIs
Publication statusPublished - 2009 Feb 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Kwon, J. S., Jang, J. H., Kang, D. H., Yoo, S. Y., Kim, Y. K., Cho, S. J., Bo, H. Y., Bum, S. J., Byung, O. L., Chan, H. K., Chang, Y. K., Pae, C. U., Chul, E. K., Do, H. K., Dong, S. Y., Jon, D. I., Kim, J. J., Jae, G. C., Seok, J. H., ... Young, H. K. (2009). Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-Week prospective study. Psychiatry and Clinical Neurosciences, 63(1), 73-81. https://doi.org/10.1111/j.1440-1819.2008.01907.x